Search

Displaying results 6991 - 7000 of 8169 in total
  1. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  2. Drug

    Relacatib

    go.drugbank.com/drugs/DB06367
    Investigational

  3. Drug

    GLB-001

    go.drugbank.com/drugs/DB32795
    Investigational

    GLB-001 is a orally bioavailable molecular glue degrader targeting casein kinase 1 alpha (CK1a).

  4. Drug

    Lonidamine

    go.drugbank.com/drugs/DB06266
    Investigational

    Lonidamine (LND) is a drug that interferes with energy metabolism of cancer cells, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK). In such way LND could impair energy-requiring ...

  5. Drug

    anti-alpha5Beta1-integrin antibody

    go.drugbank.com/drugs/DB05870
    Experimental

    Integrins are important adhesion molecules that regulate tumor and endothelial cell survival, proliferation and migration. The integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin ant...

  6. Drug

    Stamulumab

    go.drugbank.com/drugs/DB05915
    Investigational

    MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.

  7. Drug

    Becocalcidiol

    go.drugbank.com/drugs/DB04891
    Investigational

    Becocalcidiol is a vitamin D(3) analogue which has not caused hypercalcaemia or significant irritation in preclinical trials.

    Categories: Vitamin D and Analogues
  8. Drug

    Fulzerasib

    go.drugbank.com/drugs/DB21609
    Investigational

    Fulzerasib has a monoisotopic molecular weight of 630.22 Da.

  9. Drug

    NOV-002

    go.drugbank.com/drugs/DB05393
    Investigational

    NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy.

  10. Drug

    IDD-1

    go.drugbank.com/drugs/DB05439
    Experimental

    As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.